NCT05445310 is a Phase 2 clinical trial of Furmonertinib in Non-small Cell Lung Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05445310?

NCT05445310 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05445310?

Interventions in NCT05445310: Furmonertinib.

What condition does NCT05445310 study?

NCT05445310 studies Non-small Cell Lung Cancer.

Is NCT05445310 still recruiting?

NCT05445310 is currently recruiting now. Last updated 16 February 2023.

Last reviewed 2023-02-16 · How we verify

NCT05445310

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Recruiting now Phase 2 Last updated 16 February 2023

What this trial tests

Phase 2 trial testing Furmonertinib in Non-small Cell Lung Cancer in 114 participants. Currently enrolling.

Timeline

6 August 2022

Primary endpoint
1 July 2026

1 July 2026

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	114
Start date	6 August 2022
Primary completion	1 July 2026
Estimated completion	1 July 2026
Sites	1 location across China

Drugs / interventions tested

Furmonertinib — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary endpoint is the disease-free survival rate at 3 years.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI.
Ding J, Ding X, Zeng J, Liu X. · · 2024 · cited 10× · PMID 38440180 · DOI 10.3389/fphar.2024.1357913
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Fuorivia V, Attili I, Corvaja C, Asnaghi R, et al · · 2024 · cited 7× · PMID 39330007 · DOI 10.3390/curroncol31090379
Targeted therapy for stage IA non-small cell lung cancer with <i>EGFR</i> mutations: a scoping review.
Xie Y, Xia L, Niu Z, Zhang X, et al · · 2026 · PMID 42170287 · DOI 10.21037/tlcr-2025-aw-1251

Verify or expand the search:

Other trials of Furmonertinib

Trials testing the same drug.

NCT07482605 — Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion · Phase 2 · not yet recruiting
NCT07304739 — Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients · Phase 2 · recruiting
NCT07193160 — Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastati · Phase 2 · not yet recruiting
NCT06674343 — Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations · Phase 3 · recruiting
NCT06319950 — High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases · Phase 2 · not yet recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05445310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 16 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05445310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing